<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02596321</url>
  </required_header>
  <id_info>
    <org_study_id>MITI3001</org_study_id>
    <nct_id>NCT02596321</nct_id>
  </id_info>
  <brief_title>A Study Investigating the Immunologic Effects and Safety of 60-day Treatment of the ALK HDM Tablets in Adult Subjects With HDM-Induced Allergic Rhinitis and/or Atopic Asthma</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled Study Investigating the Immunologic Effects and Safety of 60-day Treatment of the ALK HDM Tablets in Adult Subjects With Allergic Rhinitis and/or Atopic Asthma Induced by House Dust Mites</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Linical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Datamap</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Abbott</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To demonstrate superiority of ALK HDM tablets versus placebo in immune response, measured as
      change of D.farinae specific immunoglobulin G4 (IgG4) from baseline to end of treatment with
      ALK HDM tablets given once daily over 60 days.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To demonstrate superiority of ALK HDM tablets versus placebo in the immune response, measured
      as change of D. Farinae specific IgG4 from baseline to end of treatment with ALK HDM tablets
      given once daily over 60 days

      To evaluate the immune response, measured as change of D. pteronyssinus, D. farinae specific
      immunoglobulin E (IgE) and D. pteronyssinus specific IgG4 from baseline to end of treatment
      with ALK HDM tablets given once daily over 60 days, compared to placebo

      To evaluate in patients with HDM-allergic respiratory disease the safety and tolerability of
      60-day treatment with ALK HDM tablets compared to placebo
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2015</start_date>
  <completion_date type="Actual">June 2016</completion_date>
  <primary_completion_date type="Actual">June 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>D. Farinae Specific IgG4 Change From Baseline to End of Treatment</measure>
    <time_frame>60 days from baseline</time_frame>
    <description>primary efficacy endpoint of D. Farinae specific IgG4 change from baseline to end of treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>D. Pteronyssinus Specific IgG4 Change From Baseline to End of Treatment</measure>
    <time_frame>60 days from baseline</time_frame>
    <description>secondary endpoint of D. pteronyssinus specific IgG4 change from baseline to end of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>D. Farinae Specific IgE Change From Baseline to End of Treatment</measure>
    <time_frame>60 days from baseline</time_frame>
    <description>the secondary endpoint of D. farinae specific IgE change from baseline to end of treatment compared to placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>D. Pteronyssinus Specific IgE Change From Baseline to End of Treatment</measure>
    <time_frame>60 days from baseline</time_frame>
    <description>the secondary endpoint of D. pteronyssinus specific IgE change from baseline to end of treatment compared to placebo</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">112</enrollment>
  <condition>Allergy</condition>
  <condition>Asthma</condition>
  <condition>Rhinitis</condition>
  <arm_group>
    <arm_group_label>Mitizax ALK HDM tablet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Standardised allergen extract from the house dust mites Dermatophagoides pteronyssinus and Dermatophagoides farinae developmental unit, dose standard for ALK HDM tablets (12DU)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo tablet</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo tablet</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mitizax</intervention_name>
    <description>Allergen extract</description>
    <arm_group_label>Mitizax ALK HDM tablet</arm_group_label>
    <other_name>ALK HDM tablet</other_name>
    <other_name>allergen extract</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo tablet</description>
    <arm_group_label>Placebo tablet</arm_group_label>
    <other_name>Placebo tablet</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent obtained before entering the study

          -  Patients 18-65 years of age, with a clinical history consistent with HDM-induced
             allergic rhinitis or allergic rhinoconjunctivitis with or without HDM-induced allergic
             atopic asthma for more than 1 year

          -  Use of symptomatic treatment of HDM-induced allergic rhinitis and/or HDM-induced
             atopic asthma, i.e. antihistamines, nasal decongestants, nasal and/or inhaled
             corticosteroid for more than 1 year

          -  if HDM-induced atopic asthma is present, it should be of mild to moderate severity,
             controlled on treatment corresponding to steps 1-3 of The Global initiative for asthma
             (GINA)

          -  Positive skin prick test response (wheal diameter ≥3 mm) to D pteronyssinus and/or
             D.farinae

          -  Moderate or higher level of D.pteronyssinus and/or D.farinae specific IgE (defined as
             ≥IgE Class 2; or ≥0.70 kilo unit (kU)/L)

          -  Patient one of the following:

               1. Male

               2. Female, infertile

               3. Female, with a negative pregnancy test and willingness to practice appropriate
                  contraceptive methods until treatment with study drug has been discontinued.

          -  Patient willing and able to comply with study protocol

        Exclusion Criteria:

          -  Previous treatment with HDM immunotherapy for more than 1 month within the last 5
             years

          -  Ongoing treatment with any allergen-specific immunotherapy product

          -  Reduced lung function (defined as Forced expiratory volume in 1 second (FEV1) &lt; 70% of
             predicted value after adequate pharmacologic treatment) measured at Visit 1 and Visit
             2

          -  Clinical history of uncontrolled asthma within 3 months prior to the screening visit

          -  Having experienced a severe asthma exacerbation within 3 months prior to screening
             visit

          -  Symptoms of or treatment for upper respiratory tract infection, acute sinusitis, acute
             otitis media or other relevant infectious process at randomization

          -  Inflammatory conditions in the oral cavity with severe symptoms such as oral lichen
             planus with ulcerations or severe oral mycosis at randomization

          -  History of anaphylaxis with cardiorespiratory symptoms (immunotherapy,
             exercise-induced, food allergy, drugs or an idiopathic reaction)

          -  History of recurrent generalized urticaria (defined as two or more episodes) during
             the last 2 years

          -  A history of drug induced (incl. immunotherapy) facial angioedema or a family (parents
             and siblings) history of hereditary angioedema

          -  Any chronic disease (e.g. cystic fibrosis, malignancy, malabsorption or malnutrition,
             renal or hepatic abnormality or any other diseases that in the opinion of the
             investigator would interfere with the study evaluations or the safety of the subject)

          -  Systemic disease affecting the immune system (e.g. autoimmune disease, immune complex
             disease, or immune deficiency disease whether acquired or not)

          -  Immunosuppressive treatment (ATC code L04 or L01) within 3 months prior to the
             screening visit

          -  Currently treated with tricyclic antidepressants; catecholamine-O-methyltransferase
             (COMT) inhibitors and mono amine oxidase inhibitors (MAOIs) and beta-blockers
             including topical administration

          -  Use of medication at the screening visit which at the time of skin prick test (SPT)
             can interfere with the result (i.e. antihistamines)

          -  Use of an investigational drug within 30 days/5 half-lives of the drug (which ever
             longest) prior to the screening visit

          -  History of allergy, hypersensitivity or intolerance to a excipient in the
             investigational medicinal product (except D.Pteronyssinus and D.farinae)

          -  Being immediate family of the investigator or study staff, defined as the
             investigator's/staff's spouse, parent, child, grandparent or grandchild

          -  Severe mental disorders that in the opinion of the investigator would interfere with
             the study evaluations or the safety of the subject

          -  Cardiovascular conditions in which complications are possible when using adrenaline

          -  Women who are pregnant or breastfeeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dmitri Kazei, MD</last_name>
    <role>Study Director</role>
    <affiliation>Abbott</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Minsk Regional Clinical Hospital</name>
      <address>
        <city>Minsk</city>
        <zip>220041</zip>
        <country>Belarus</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Clinical Hopsital #10</name>
      <address>
        <city>Minsk</city>
        <zip>220096</zip>
        <country>Belarus</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kazan State Medical Academy</name>
      <address>
        <city>Kazan</city>
        <zip>420103</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Research Center - Institute of Immunology Federal Medical-Biological Agency of Russia</name>
      <address>
        <city>Moscow</city>
        <zip>115478</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>&quot;Russian Medical Academy of Postgraduate Education Studies</name>
      <address>
        <city>Moscow</city>
        <zip>123182</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City out-patient's clinic # 94</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>193231</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Smolensk State Medical Academy</name>
      <address>
        <city>Smolensk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital of Russian Academy of Science</name>
      <address>
        <city>Troitsk</city>
        <zip>142190</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bashkirskiy State Medical University</name>
      <address>
        <city>Ufa</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belarus</country>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 2, 2015</study_first_submitted>
  <study_first_submitted_qc>November 3, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 4, 2015</study_first_posted>
  <results_first_submitted>July 21, 2017</results_first_submitted>
  <results_first_submitted_qc>July 21, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">December 18, 2017</results_first_posted>
  <last_update_submitted>February 1, 2018</last_update_submitted>
  <last_update_submitted_qc>February 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 1, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>House Dust Mite</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Rhinitis, Allergic</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Mitizax ALK HDM Tablet</title>
          <description>Standardised allergen extract from the house dust mites Dermatophagoides pteronyssinus and Dermatophagoides farinae developmental unit, dose standard for ALK HDM tablets (12DU)
Mitizax: Allergen extract</description>
        </group>
        <group group_id="P2">
          <title>Placebo Tablet</title>
          <description>Placebo tablet
Placebo: Placebo tablet</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="56"/>
                <participants group_id="P2" count="56"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="53"/>
                <participants group_id="P2" count="56"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Mitizax ALK HDM Tablet</title>
          <description>Standardised allergen extract from the house dust mites Dermatophagoides pteronyssinus and Dermatophagoides farinae developmental unit, dose standard for ALK HDM tablets (12DU)
Mitizax: Allergen extract</description>
        </group>
        <group group_id="B2">
          <title>Placebo Tablet</title>
          <description>Placebo tablet
Placebo: Placebo tablet</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="56"/>
            <count group_id="B2" value="56"/>
            <count group_id="B3" value="112"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="53"/>
                    <measurement group_id="B2" value="55"/>
                    <measurement group_id="B3" value="108"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31.7" spread="9.1"/>
                    <measurement group_id="B2" value="31.4" spread="9.8"/>
                    <measurement group_id="B3" value="31.6" spread="9.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="59"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Belarus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Russia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="44"/>
                    <measurement group_id="B3" value="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>D. Farinae Specific IgG4 Change From Baseline to End of Treatment</title>
        <description>primary efficacy endpoint of D. Farinae specific IgG4 change from baseline to end of treatment</description>
        <time_frame>60 days from baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Mitizax ALK HDM Tablet</title>
            <description>Standardised allergen extract from the house dust mites Dermatophagoides pteronyssinus and Dermatophagoides farinae developmental unit, dose standard for ALK HDM tablets (12DU)
Mitizax: Allergen extract</description>
          </group>
          <group group_id="O2">
            <title>Placebo Tablet</title>
            <description>Placebo tablet
Placebo: Placebo tablet</description>
          </group>
        </group_list>
        <measure>
          <title>D. Farinae Specific IgG4 Change From Baseline to End of Treatment</title>
          <description>primary efficacy endpoint of D. Farinae specific IgG4 change from baseline to end of treatment</description>
          <units>mg antibody/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.473" spread="1.183"/>
                    <measurement group_id="O2" value="-0.01" spread="0.067"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>D. Pteronyssinus Specific IgG4 Change From Baseline to End of Treatment</title>
        <description>secondary endpoint of D. pteronyssinus specific IgG4 change from baseline to end of treatment</description>
        <time_frame>60 days from baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Mitizax ALK HDM Tablet</title>
            <description>Standardised allergen extract from the house dust mites Dermatophagoides pteronyssinus and Dermatophagoides farinae developmental unit, dose standard for ALK HDM tablets (12DU)
Mitizax: Allergen extract</description>
          </group>
          <group group_id="O2">
            <title>Placebo Tablet</title>
            <description>Placebo tablet
Placebo: Placebo tablet</description>
          </group>
        </group_list>
        <measure>
          <title>D. Pteronyssinus Specific IgG4 Change From Baseline to End of Treatment</title>
          <description>secondary endpoint of D. pteronyssinus specific IgG4 change from baseline to end of treatment</description>
          <units>mg antibody/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.455" spread="1.210"/>
                    <measurement group_id="O2" value="0.001" spread="0.076"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>D. Farinae Specific IgE Change From Baseline to End of Treatment</title>
        <description>the secondary endpoint of D. farinae specific IgE change from baseline to end of treatment compared to placebo</description>
        <time_frame>60 days from baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Mitizax ALK HDM Tablet</title>
            <description>Standardised allergen extract from the house dust mites Dermatophagoides pteronyssinus and Dermatophagoides farinae developmental unit, dose standard for ALK HDM tablets (12DU)
Mitizax: Allergen extract</description>
          </group>
          <group group_id="O2">
            <title>Placebo Tablet</title>
            <description>Placebo tablet
Placebo: Placebo tablet</description>
          </group>
        </group_list>
        <measure>
          <title>D. Farinae Specific IgE Change From Baseline to End of Treatment</title>
          <description>the secondary endpoint of D. farinae specific IgE change from baseline to end of treatment compared to placebo</description>
          <units>kUA/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="140.37" spread="288.15"/>
                    <measurement group_id="O2" value="-5.56" spread="16.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>D. Pteronyssinus Specific IgE Change From Baseline to End of Treatment</title>
        <description>the secondary endpoint of D. pteronyssinus specific IgE change from baseline to end of treatment compared to placebo</description>
        <time_frame>60 days from baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Mitizax ALK HDM Tablet</title>
            <description>Standardised allergen extract from the house dust mites Dermatophagoides pteronyssinus and Dermatophagoides farinae developmental unit, dose standard for ALK HDM tablets (12DU)
Mitizax: Allergen extract</description>
          </group>
          <group group_id="O2">
            <title>Placebo Tablet</title>
            <description>Placebo tablet
Placebo: Placebo tablet</description>
          </group>
        </group_list>
        <measure>
          <title>D. Pteronyssinus Specific IgE Change From Baseline to End of Treatment</title>
          <description>the secondary endpoint of D. pteronyssinus specific IgE change from baseline to end of treatment compared to placebo</description>
          <units>kUA/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="124.85" spread="286.90"/>
                    <measurement group_id="O2" value="-5.16" spread="27.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Mitizax ALK HDM Tablet</title>
          <description>Standardised allergen extract from the house dust mites Dermatophagoides pteronyssinus and Dermatophagoides farinae developmental unit, dose standard for ALK HDM tablets (12DU)
Mitizax: Allergen extract</description>
        </group>
        <group group_id="E2">
          <title>Placebo Tablet</title>
          <description>Placebo tablet
Placebo: Placebo tablet</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oral soft tissue signs and symptoms</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="56"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Tongue signs and symptoms</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="56"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infections</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headaches NEC</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="56"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Upper raspiratory tract signs and symptoms</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="56"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Therapeutic Area Clinical Director</name_or_title>
      <organization>Abbott</organization>
      <phone>+31294477008</phone>
      <email>dmitri.kazei@abbott.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

